HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Develop Unapproved Narcotic Analgesic in Japan
March 26, 2012
- Suzuken Establishes New Company Specializing in Rare Diseases
March 26, 2012
- Nexium No. 1 in MR Call Frequency in HP Market in February: Rep Track Survey
March 26, 2012
- Break of Day-Working to Optimize Settai Practices, Increase Financial Transparency: 3
March 26, 2012
- Break of Day-Working to Optimize Settai Practices, Increase Financial Transparency: 4
March 26, 2012
- Bayer Yakuhin to Initiate Drug Use-Result Survey on 10,000 Patients for Xarelto
March 23, 2012
- Shionogi Submits PIIa Clinical Trial Application for OncoTherapy’s AMD Vaccine
March 23, 2012
- Ajinomoto Pharmaceuticals to Market Gastritis/Ulcer Treatment Marzulene from July
March 23, 2012
- Astellas Vice Deputy Chairman Ishii Says Company R&D Strategy Focused on Personalized Medicine
March 22, 2012
- India’s Ministry of Commerce and Industry Kicks Off “Brand India Pharma” Campaign
March 22, 2012
- BD Japan Seeking Further Partnerships with Japanese Companies: Pres. Harris
March 22, 2012
- MTPC, Novartis Revise Package Insert of Imusera/Gilenya in Response to Overseas Death
March 22, 2012
- MSD, BIKEN Sign Domestic Marketing Agreement for 3 Flu Vaccines
March 22, 2012
- Taiho Pharmaceutical Launches TS-1 in 4 Scandinavian Countries
March 22, 2012
- Acquisition by Lupin Improves Kyowa Pharmaceutical Industry’s Profitability: President Tsunoda
March 21, 2012
- Break of Day-Working to Optimize Settai Practices, Increase Financial Transparency: 1
March 19, 2012
- Break of Day-Working to Optimize Settai Practices, Increase Financial Transparency: 2
March 19, 2012
- Nichi-Iko Definitely to Enter as Global Top-10 Generics Company within 4 Years: President Tamura
March 16, 2012
- Fuji-Keizai Predicts Japan’s Generics Market to Exceed ¥580 Billion in 2014
March 16, 2012
- All-Case PMS for Sutent Lifted: Pfizer
March 16, 2012
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…